Quarterly Orders and Revenue Growth
Q4 orders increased 8% year-over-year (organic +1%); Q4 revenue rose 10% year-over-year (organic revenue +3%), signaling positive momentum into 2026.
Strong Adjusted EBITDA and Margins
Q4 adjusted EBITDA was $580 million with a margin of 27.7%; full-year adjusted EBITDA approximately $2.1 billion with a 27.4% margin, exceeding the upper end of prior guidance.
Earnings Per Share Improvements
Q4 adjusted EPS was $0.96 (up 14% year-over-year); full-year adjusted EPS $3.34, up 2% year-over-year; 2026 guidance of $3.45–$3.57 implies ~5% growth at the midpoint.
Recurring Revenue Acceleration
Recurring revenue exceeded $450 million in 2025 with a backlog of approximately $1.1 billion of future contracted revenue, up materially from roughly $200 million a few years prior.
Robust M&A Execution and Pipeline
Invested $525 million across 16 transactions in 2025 generating ~ $275 million in annualized inorganic revenue (average ~9x presynergy multiple); nine additional transactions currently under LOI and Synomics closed in January 2026.
Strong Capital Deployment and Balance Sheet
Deployed $1.0 billion in share repurchases and $32 million in dividends in 2025; $3.8 billion in liquidity, leverage well under 2x, Q4 cash flow $462 million.
Segment-Level Strength — PST Life Sciences
PST Q4 orders up 6% YoY (organic +1%), life sciences organic orders up mid-teens; Q4 PST revenue +8% YoY (organic +4%); PST adjusted EBITDA $127 million, up 19% YoY with a 30.4% margin (+280 bps YoY).
Regional and Product Wins, Including China
ITS Q4 orders up 9% (organic low single digits); Asia Pacific showed strong growth (APAC up low double digits, China up low single digits, rest of Asia mid-twenties); three consecutive quarters of organic growth in China attributed to localized product launches and technology integrations.